Druggable molecular targets for the treatment of triple negative breast cancer
Version 3 2024-06-19, 06:44
Version 2 2024-06-13, 14:54
Version 1 2021-11-22, 10:33
journal contribution
posted on 2024-06-19, 06:44 authored by M Nakhjavani, JE Hardingham, HM Palethorpe, TJ Price, AR TownsendDruggable molecular targets for the treatment of triple negative breast cancer
History
Journal
Journal of Breast CancerVolume
22Pagination
341-361Location
Korea (South)Publisher DOI
Open access
- Yes
Link to full text
ISSN
1738-6756eISSN
2092-9900Language
EnglishPublication classification
C1 Refereed article in a scholarly journalIssue
3Publisher
KOREAN BREAST CANCER SOCUsage metrics
Categories
No categories selectedKeywords
Science & TechnologyLife Sciences & BiomedicineOncologyClinical trialDrug therapyTriple negative breast neoplasmsRANDOMIZED PHASE-IICONJUGATE GLEMBATUMUMAB VEDOTINBEVACIZUMAB-CONTAINING THERAPYTRANSFORMING-GROWTH-FACTORFACTOR RECEPTORMESSENGER-RNABRCA MUTATIONCHEMOTHERAPYTRIALINHIBITION3211 Oncology and carcinogenesis3214 Pharmacology and pharmaceutical sciences
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC